Weight Loss & Fat Loss Peptides

Advanced Obesity Drug 9604, hGH Fragment 176-191

AOD-9604 is a synthetic fragment of the human growth hormone molecule, corresponding to amino acids 176–191 of the C-terminus. It is researched specifically for its lipolytic properties and is considered a lower-risk alternative to full growth hormone analogues for body composition research, given its apparent lack of effect on insulin sensitivity or IGF-1 levels.

AM833

A once-weekly long-acting amylin analogue in late-stage development. Showing impressive weight loss (~15%) in trials, especially when combined with semaglutide (CagriSema).

CJC-1295 DAC, Drug Affinity Complex GHRH

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) form binds to albumin in the bloodstream, extending its half-life to several days and enabling sustained elevation of GH and IGF-1 levels. It is commonly researched alongside GHRP peptides for body composition and recovery outcomes.

Victoza, Saxenda

A GLP-1 receptor agonist used for weight management and type 2 diabetes. Reduces appetite and promotes significant fat loss.

Symlin, AC0137

FDA-approved synthetic amylin analogue that complements insulin therapy. Reduces postprandial glucose spikes and suppresses appetite, aiding weight management in T1D and T2D.

LY3437943

A triple agonist peptide in clinical development showing exceptional weight loss results (up to 24% body weight). Targets GIP, GLP-1, and glucagon receptors simultaneously.

Ozempic, Wegovy, Rybelsus

Semaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). It is among the most prescribed and searched compounds in the weight loss space. Compounding pharmacies have produced semaglutide formulations under 503A and 503B frameworks, with significant provider interest across the telehealth and functional medicine space. Its mechanism involves both peripheral and central appetite suppression.

Egrifta, TH9507

Tesamorelin is a stabilised analogue of endogenous growth hormone-releasing hormone (GHRH). It holds FDA approval for the treatment of HIV-associated lipodystrophy and is the most clinically studied GHRH analogue. Outside its approved indication, it is researched for visceral fat reduction, cognitive function, and metabolic health in older adults.

Mounjaro, Zepbound, Dual GLP-1

Tirzepatide is a once-weekly injectable dual agonist of GLP-1 and GIP receptors, FDA approved for type 2 diabetes (Mounjaro) and weight management (Zepbound). Clinical trials demonstrate weight reductions exceeding those seen with semaglutide in head-to-head comparisons. Compounded formulations are offered by telehealth and functional medicine providers across the US. It represents the current clinical frontier in pharmacological weight management.